2009 unambiguously marked a thawing of the bio IPO market – who froze up at the tail end of 2007 – by featuring six offerings, and a seventh filed that may still travel along the neon lights of the midtown Manhattan Nasdaq ticker before we see Dick Clark and friends ring in 2010 from just [...]

• 566http://clsdf.com/2009/10/2010-impending-bio-ipo-pandemonium-part-1/2010+%7C+Impending+Bio+IPO+Pandemonium%21+%28Part+%231%292009-10-31+04%3A55%3A08admin

NOTE: Apologies for the delayed post release. 22″ of October snow yielded a slow start to the day…
Waltham, MA-based Synageva Biopharma (formerly AviGenics) is focused on novel, next-generation and follow-on protein therapeutics that leverage their Synageva Expression Platform (SEP™). SEP™ is an integrated platform of proprietary vectors and protein production, processing and purification systems [...]

• 561http://clsdf.com/2009/10/synageva-biopharma-series-c-45m/Synageva+BioPharma+%7C+Series+C+%2445M2009-10-29+17%3A55%3A15admin

[Update #3] This is fast becoming perhaps my favorite post to update because it is the catalytic properties of the sometimes elusive to isolate GREEN enzyme that can enable so much good. That said, today’s new fund to report on, Mission Bay Capital (no website, yet…), though small in size, it is a seed fund [...]

• 556http://clsdf.com/2009/10/update-3-looking-for-some-more-of-this/UPDATE+%233+%7C+Looking+for+Some+%28MORE%29+of+This%3F2009-10-28+14%3A36%3A33admin

We recently reported on the AGA Medical (NASDAQ: AGAM) – developer of interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders – public filing intentions and can now follow-up with their initial public offering debut details and as well check in with AGA’s Bio IPO class of 2009 brethren. [...]

• 546http://clsdf.com/2009/10/aga-medical-bang-off-and-running%e2%80%a6/AGA+Medical+%7C+BANG%21+Off+and+Running%E2%80%A6+2009-10-27+14%3A35%3A13admin

Aliso Viejo, CA-based Vertos Medical is a medical device company focused on providing minimally invasive alternatives for surgical procedures to treat lumbar spinal stenosis (LSS) a degenerative, age-related narrowing of the lower spinal canal.. The Company’s first proprietary platform technology, MILD® (Minimally Invasive Lumbar Decompression), is the first minimally invasive surgical treatment for LSS.
Can you [...]

• 541http://clsdf.com/2009/10/vertos-medical-series-d-15-5m/Vertos+Medical+%7C+Series+D+%2415.5M2009-10-26+06%3A02%3A03admin

[Update #2] A bold call? Perhaps… As 2009 winds down with about ten weeks to go it sounds as if one should not be surprised that large stockpiles of cash move from the sideline, tighten the chinstrap and get in the game – from limited partners to funds to institutions – who move to [...]

• 527http://clsdf.com/2009/10/update-2-looking-for-some-of-this/UPDATE+%232+%7C+Looking+for+Some+of+This%3F2009-10-23+13%3A49%3A04admin

GlycoMimetics (GMI), based in Gaithersburg, MD, was founded via the acquisition of assets and expertise from GlycoTech, who developed technology to identify and assay carbohydrate mimics initially through a collaboration with Ciba-Geigy, now Novartis (NYSE: NVS), and then independently. These assay capabilities were out-licensed to Wyeth, now Pfizer (NYSE: PFE). Today, GMI holds or has [...]

• 520http://clsdf.com/2009/10/glycomimetics-series-c-38m/GlycoMimetics+%7C+Series+C+%2438M2009-10-22+15%3A25%3A16admin

Lux Biosciences, based in Jersey City, NJ and focused upon the development of ophthalmic disease, has relied upon an in-licensing strategy from corporate partners and academia for molecules and technologies that have demonstrated proof-of-concept in related non-ophthalmic diseases but where common mechanisms of action and biological pathway overlap may be levered.
PRODUCTS IN DEVELOPMENT
LX211, Luveniq™ (granted [...]

• 510http://clsdf.com/2009/10/lux-biosciences-series-b-50m/Lux+Biosciences+%7C+Series+B+%2450M2009-10-21+14%3A52%3A57admin

There is some robust and diverse activity transpiring at West Lafayette, IN-based Endocyte where not one, not two but three unique business activities are transpiring concurrently. These include:

Addressing the issues of dosing and toxicity of oncologic therapeutics via a drug guidance system which is intended to improve specificity, safety and efficacy, and is payload agnostic [...]

• 502http://clsdf.com/2009/10/endocyte-series-c-26m/Endocyte+%7C+Series+C+%2426M2009-10-20+14%3A33%3A50admin

The name Leroy Hood may ring a bell to some (or most); Dr. Hood is considered among the uber-distinguished handful of architects of the molecular biotechnology revolution based upon his co-development of DNA and protein synthesis and sequencing technologies. These breakthrough contributions catalyzed the foundation of an industrial revolution, in addition Dr. Hood played a [...]

• 491http://clsdf.com/2009/10/integrated-diagnostics-series-a-30-1m/Integrated+Diagnostics+%7C+Series+A+%2430.1M2009-10-19+03%3A54%3A49admin

Thanks very much for your patience as we work diligently to re-launch the Life Science Deal Flow blog. We will be back on online Monday 19 October, not necessarily rested rather getting after it to bring you the latest on early-stage therapeutic, diagnostic and device companies – the news breaking, the funds raised, the investors [...]

• 457http://clsdf.com/2009/10/we%e2%80%99ll-be-right-back/We%E2%80%99ll+Be+Right+Back%212009-10-13+15%3A29%3A35admin

Omeros (NASDAQ: OMER) launched itself onto the Nasdaq global marketplace yesterday with its initial public offering of 6.82M shrs priced at $10 raising approximately $68M less underwriting expenses. Its foray however, was more dud then thud relative to its peers in the Biopharma IPO Class of 2009. For Omeros is the only clinical-stage, pre-commercial, pre-revenue [...]

• 456http://clsdf.com/2009/10/omeros-lackluster-ipo-debut-a-good-sign/Omeros+%7C+Lackluster+IPO+Debut+a+Good+Sign%3F2009-10-09+13%3A38%3A00admin

AGA Medical (Plymouth, MN) developer of interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders, first filed with the intention to reach the public market in 2008 (‘nuff said), now on the heels of what is shaping up to be, dare one say, an active 2H09 life science IPO [...]

• 455http://clsdf.com/2009/10/aga-medical-holdings-back-in-the-queue/AGA+Medical+Holdings+%7C+Back+in+the+Queue2009-10-08+14%3A15%3A00admin